Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: A single center prospective survey in adult Italians

American Journal of Hematology

Volumn 88, Issue 11, 2013, Pages

  Rigano, Paolo ^a   Pecoraro, Alice ^a   Calvaruso, Giuseppina ^a   Steinberg, Martin H ^b   Iannello, Sonia ^a   Maggio, Aurelio ^a  

^a AO Ospedali Riuniti Villa Sofia Cervello   (Italy)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN F; HYDROXYUREA;

ADULT; AGED; ARTICLE; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL EVALUATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; ITALY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; SICKLE CELL BETA THALASSEMIA; SICKLE CELL CRISIS; TREATMENT RESPONSE;

ADULT; AGED; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; BETA-THALASSEMIA; CEREBRAL INFARCTION; CEREBROVASCULAR DISORDERS; DISEASE PROGRESSION; FEMALE; FETAL HEMOGLOBIN; FOLLOW-UP STUDIES; HETEROZYGOTE; HUMANS; HYDROXYUREA; INCIDENCE; ITALY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SICKLE CELL TRAIT; STROKE; YOUNG ADULT;

EID: 84886285493     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23531     Document Type: Article

References (36)

1. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998;339:5-11.
2. Miller ST, Macklin EA, Pegelow CH, et al. Cooperative Study of Sickle Cell Disease. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: A report from the Cooperative Study of Sickle Cell Disease. J Pediatr 2001;139:385-390.
3. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: Rates and risk factors. Blood 1998;91:288-294.
4. Casella JF, King AA, Barton B, et al. Design of the silent cerebral infarct transfusion (SIT) trial. Pediatr Hematol Oncol 2010;27:69-89.
5. DeBaun MR, Sarnaik SA, Rodeghier MJ, et al. Associated risk factors for silent cerebral infarcts in sickle cell anemia: Low baseline hemoglobin, gender and relative high systolic blood pressure. Blood 2011;119:3684-3690.
6. Pegelow CH, Macklin EA, Moser FG, et al. Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood 2002;99:3014-3018.
7. DeBaun MR, Armstrong FD, McKinstry RC, et al. Silent cerebral infarcts: A review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood 2012;119:4587-4596.
8. Scothorn DJ, Price C, Schwartz D, et al. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr 2002;140:48-54.
9. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995;332:1317-1322.
10. De Montalembert M, Belloy M, Bernaudin F, et al. for the French Study Group on Sickle Cell Disease. Three years follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. J Pediatr Hematol/Oncol 1997;19:313-318.
11. Rigano P, Rodgers GP, Renda D, et al. Clinical and hematological responses to hydroxyurea in sicilian patients with HbS/beta-thalassemia. Hemoglobin 2001;25:9-17.
12. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. JAMA 2003;289:1645-1651.
13. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia and MSH Patients' Follow-Up. Am J Hematol 2010;85:403-408.
14. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: Results of a 17-year, single-center trial (LaSHS). Blood 2010;115:2354-2363.
15. Gulbis B, Haberman D, Dufour D, et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: The Belgian experience. Blood 2005;105:2685-2690.
16. Lefèvre N, Dofour D, Gulbis B, et al. Use of hydroxyurea in prevention of stroke in children with sickle cell disease. Blood 2008;111:963-964.
17. Zimmerman SA, Schultz WH, Burgett S, et al. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood 2007;110:1043-1047.
18. Ware RE, Helms RW, SWiTCH Investigators. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood 2012;119:3925-3932.
19. Bernaudin F, Socie G, Kuentz M, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 2007;110:2749-2756.
20. Woodard P, Helton KJ, Khan RB, et al. Brain parenchymal damage after haematopoietic stem cell transplantation for severe sickle cell disease. Br J Haematol 2005;129:550-552.
21. Zafeiriou DI, Prengler M, Gombakis N, et al. Central nervous system abnormalities in asymptomatic young patients with Sbeta-thalassemia. Ann Neurol 2004;55:835-839.
22. Marouf R, Gupta R, Haider MZ, Adekile AD. Silent brain infarcts in adult Kuwaiti sickle cell disease patients. Am J Hematol 2003;73:240-243.
23. Bernaudin F, Verlhac S, Freard F, et al. Multicenter prospective study of children with sickle cell disease: Radiographic and psychometric correlation. J Child Neurol 2000;15:333-343.
24. Manfre L, Giarratano E, Maggio A, et al. MR imaging of the brain: Findings in asymptomatic patients with thalassemia intermedia and sickle cell-thalassemia disease. AJR Am J Roentgenol 1999;173:1477-1480.
25. Kinney TR, Sleeper LA, Wang WC, et al. Silent cerebral infarcts in sickle cell anemia: A risk factor analysis. The Cooperative Study of Sickle Cell Disease. Pediatrics 1999;103:640-645.
26. Kwiatkowski JL, Zimmerman RA, Pollock AN, et al. Silent infarcts in young children with sickle cell disease. Br J Haematol 2009;146:300-305.
27. Hulbert ML, McKinstry RC, Lacey JL, et al. Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood 2011;117:772-779.
28. Schatz J., Brown RT, Pascual JM, et al. Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease. Neurology 2001;56:1106-1111.
29. Schatz J, White DA, Moinuddin A, Lesion burden and cognitive morbidity in children with sickle cell disease. J Child Neurol 2002;17:891-895.
30. Vichinsky EP, Neumayr LD, Gold JI, et al. Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia. JAMA 2010;303:1823-1831.
31. Morris CR. Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematology Am Soc Hematol Educ Prog 2008:177-185.
32. Platt OS. Preventing stroke in sickle cell anemia. New Engl J Med 2005;353:2743-2745.
33. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 2007;21:37-47.
34. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004;350:886-895.
35. Nouraie M, Lee JS, Zhang Y, et al. The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica 2013;98:464-472.
36. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: A multicentre, randomised, controlled trial (BABY HUG). Lancet 2011;377:1663-1672.